Abstract
The purpose of the current study was to evaluate size-tuneable polymeric glycol-chitosan (GC)-DTPAGadolinium (Gd) conjugates as MRI contrast agents that can be used as a platform for imaging of molecular weight (MW) dependent transport processes. GC-DTPA-Gd conjugates of precisely controlled MWs were synthesised and evaluated in mice against Gd-DTPA using time series of high-resolution MRI images of trunk, head, and xenograft flank tumours. GC-DTPA modification ratio was one DTPA per 3.9-5.13 of GC monomers. GC-DTAP-Gd provided overall superior contrast compared to Gd-DTPA with the duration of the enhancement depending on MW (≥1hr for 40kD). The kidneys showed early enhancement also, particularly in the renal pelvis, suggesting renal elimination. Imaging of the head with GC-DTPA-Gd allowed detailed anatomical identification of specific blood vessels in particular with the high MW CA agent. Sequential, high-resolution, isotropic imaging of established A431 xenograft flank tumours with DTPA-Gd and GC-DTPA-Gd demonstrated that the initial distribution of the contrast agents was well correlated with blood vessels and supply. In contrast, subsequent tissue transport was primarily by diffusion and limited by CA molecular weight. The data also highlight the role of heterogeneity in CA distribution which was more prominent for the high MW agent. Precise control of glycol chitosan (GC) polymer chemistry facilitates synthesis of a family of Gd-based MRI contrast agents of tuneable MW but otherwise identical physicochemical properties. Such agents allow isotropic high-resolution threedimensional imaging of MW dependent transport processes relevant to the clinical and pre-clinical prediction of drug transport processes.
Keywords: Gadolinium, glycol chitosan, molecular weight, MRI contrast agents.
Graphical Abstract
Pharmaceutical Nanotechnology
Title:Size-tuneable Nanometric MRI Contrast Agents for the Imaging of Molecular Weight Dependent Transport Processes
Volume: 2 Issue: 3
Author(s): Mazen M. El-Hammadi, Steven MacLellan, Christine Dufes, William M. Holmes, Barrie Condon, Ijeoma F. Uchegbu and Andreas G. Schatzlein
Affiliation:
Keywords: Gadolinium, glycol chitosan, molecular weight, MRI contrast agents.
Abstract: The purpose of the current study was to evaluate size-tuneable polymeric glycol-chitosan (GC)-DTPAGadolinium (Gd) conjugates as MRI contrast agents that can be used as a platform for imaging of molecular weight (MW) dependent transport processes. GC-DTPA-Gd conjugates of precisely controlled MWs were synthesised and evaluated in mice against Gd-DTPA using time series of high-resolution MRI images of trunk, head, and xenograft flank tumours. GC-DTPA modification ratio was one DTPA per 3.9-5.13 of GC monomers. GC-DTAP-Gd provided overall superior contrast compared to Gd-DTPA with the duration of the enhancement depending on MW (≥1hr for 40kD). The kidneys showed early enhancement also, particularly in the renal pelvis, suggesting renal elimination. Imaging of the head with GC-DTPA-Gd allowed detailed anatomical identification of specific blood vessels in particular with the high MW CA agent. Sequential, high-resolution, isotropic imaging of established A431 xenograft flank tumours with DTPA-Gd and GC-DTPA-Gd demonstrated that the initial distribution of the contrast agents was well correlated with blood vessels and supply. In contrast, subsequent tissue transport was primarily by diffusion and limited by CA molecular weight. The data also highlight the role of heterogeneity in CA distribution which was more prominent for the high MW agent. Precise control of glycol chitosan (GC) polymer chemistry facilitates synthesis of a family of Gd-based MRI contrast agents of tuneable MW but otherwise identical physicochemical properties. Such agents allow isotropic high-resolution threedimensional imaging of MW dependent transport processes relevant to the clinical and pre-clinical prediction of drug transport processes.
Export Options
About this article
Cite this article as:
M. El-Hammadi Mazen, MacLellan Steven, Dufes Christine, M. Holmes William, Condon Barrie, F. Uchegbu Ijeoma and G. Schatzlein Andreas, Size-tuneable Nanometric MRI Contrast Agents for the Imaging of Molecular Weight Dependent Transport Processes, Pharmaceutical Nanotechnology 2014; 2 (3) . https://dx.doi.org/10.2174/2211738503999141222224739
DOI https://dx.doi.org/10.2174/2211738503999141222224739 |
Print ISSN 2211-7385 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-7393 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanomedicine based on Nucleic Acids: Pharmacokinetic and Pharmacodynamic Perspectives
Current Pharmaceutical Biotechnology Non-Homologous DNA End Joining in Anticancer Therapy
Current Cancer Drug Targets Carbon Nanotubes in the Treatment of Skin Cancers: Safety and Toxic ological Aspects
Pharmaceutical Nanotechnology Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds Recent Advances in the Development of 14-Alkoxy Substituted Morphinans as Potent and Safer Opioid Analgesics
Current Medicinal Chemistry HIF-1α and Calcium Signaling as Targets for Treatment of Prostate Cancer by Cardiac Glycosides
Current Cancer Drug Targets Recent Advancements in Nanodiamond Mediated Brain Targeted Drug Delivery and Bioimaging of Brain Ailments: A Holistic Review
Pharmaceutical Nanotechnology p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design The Regulation of Neuroimmune-Endocrine Interactions: Mechanisms,Molecular Pathways Unraveled and the Pivotal Role of Cytokines – A Unsung Putative Bidirectional Interdependence between the Immune and Neuroendocrine Interfaces
Current Immunology Reviews (Discontinued) Defensins and Other Biocidal Proteins from Bean Seeds with Medicinal Activities
Current Medicinal Chemistry Recent Patents on Anti-Cancer Potential of Helenalin
Recent Patents on Anti-Cancer Drug Discovery Radioimmunotherapy of Cancer Using Monoclonal Antibodies to Target Radiotherapy
Current Pharmaceutical Design Modification of Decoy Oligodeoxynucleotides to Achieve the Stability and Therapeutic Efficacy
Current Topics in Medicinal Chemistry Nanocarriers to Solid Tumors: Considerations on Tumor Penetration and Exposure of Tumor Cells to Therapeutic Agents
Current Pharmaceutical Biotechnology Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs Preliminary Analysis of Anti-proliferative, Apoptotic, and Anti-migratory Effects llw-3-6 in Skov-3 Ovarian Cystadenocarcinoma Cell Line
Letters in Drug Design & Discovery Bortezomib Enhances the Antitumor Effects of Interferon-β Gene Transfer on Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry The Development of Future Research Strategies from Reviewing Antiemetic Trials for Chemotherapy Induced Emesis
Reviews on Recent Clinical Trials Possible Role of NUCB2/nesfatin-1 in Adipogenesis
Current Pharmaceutical Design MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets